Analgesic tolerance is partially mediated by enhanced glutamatergic transmission in the CNS. b-lactam antibiotics, through glutamate transporter subtype 1 (GLT-1) activation, reduce extracellular glutamate levels and attenuate tolerance to morphine analgesia in rats. Similar to opioids, nicotine has potent analgesic properties that are subject to tolerance. The purpose of this study was to evaluate the effects of ceftriaxone, a b-lactam antibiotic and GLT-1 activator on nicotine antinociception and its tolerance. Rats were pretreated for 5 days with ceftriaxone (200 mg/kg, intraperitoneally) before evaluating their analgesic response to nicotine (1.0 or 2.5 mg/kg, subcutaneously) for seven consecutive days using the tailflick assay. Ceftriaxone-treated rats displayed an enhanced antinociceptive response to nicotine and unlike salineinjected controls, did not develop tolerance to nicotine's analgesic effects. These results suggest that GLT-1 transporter activation enhances and preserves nicotine antinociception and identify b-lactam antibiotics as potential complementary therapeutic agents for the treatment of chronic pain. NeuroReport 22:970-973
Introduction
The analgesic effects of nicotine are long established [1] and have been extensively characterized (reviewed in [2] ). Nicotine antinociception is subject to tolerance, which has been documented by both acute [3, 4] and chronic [5, 6] administration paradigms, yet the mechanism of nicotine's analgesic tolerance is not clear. Several neurotransmitter and neuropeptide systems have been demonstrated to play a role in cholinergic analgesia (see [7] for review). Among these, the glutamatergic system has received considerable attention as a mediator of nociceptive sensation and transmission. Both ionotropic and metabotropic glutamate receptors are expressed in brain areas responsible for pain processing and a majority of evidence suggests that glutamate antagonists, especially mGlu1 antagonists, might be effective broad-spectrum analgesics (reviewed in [8] ). It also suggests that attenuating glutamatergic transmission might enhance the effectiveness of known analgesics.
Clearance of extracellular glutamate by the glutamate transporter (GLT-1) is the primary mechanism for terminating glutamatergic neurotransmission. The widely used and well-tolerated b-lactam class of antibiotics have recently been shown to activate and increase the expression of GLT-1 [9] and to produce a dosedependent reduction in brain glutamate levels that persist for 20 days after discontinuation of drug exposure [10] . Recent pain studies have shown that the b-lactam antibiotic ceftriaxone attenuates neuropathic pain [11] , reduce morphine [12] and cannabinoid [13] analgesic tolerance, and reduce mechanical allodynia and hyperalgesia [14] . The current study evaluated the effect of ceftriaxone on nicotine analgesia. Results demonstrate that ceftriaxone both enhances acute nicotine analgesia and prevents nicotine analgesic tolerance.
Methods

Animals and drug administration
Forty, male Sprague-Dawley rats, (Charles River Laboratories, Wilmington, Massachusetts, USA) weighing 180-210 g were housed in pairs on a 12-h light/dark schedule and had ad-libidum access to food and water. Animals were handled daily for 1 week before the start of the study. All procedures were consistent with the National Institutes of Health Guide for Care and Use of Laboratory Animals (National Institutes of Health Publication Number 80-23) and all experimental protocols were approved by the Connecticut College Institutional Animal Care and Use Committee. Ceftriaxone, (American Regent Inc., Shirley, New York, USA) was dissolved in sterile saline at a concentration of 200 mg/ml. Nicotine hydrogen tartrate (Sigma-Aldrich, St. Louis, Missouri, USA) was dissolved in sterile saline at concentrations of 2.5 and 1.0 mg/ml, calculated from the weight of the salt. Animals received daily intraperintoneal injections of ceftriaxone (200 mg/kg) or saline (1.0 mg/ml) for 5 days before the start of analgesia assessment and through the duration of testing. All animals also received subcutaneous injections of nicotine (1.0 or 2.5 mg/kg) in the nape of the neck immediately before the start of analgesia testing. Rats were divided into five groups as follows: ceftriaxone/nicotine, 2.5 mg/kg (N = 8); saline/nicotine, 2.5 mg/kg (N = 8); ceftriaxone/nicotine, 1.0 mg/kg (N = 8); saline/nicotine, 1.0 mg/kg (N = 8); saline/saline (N = 8).
Procedure
Nicotine analgesia was assessed on seven consecutive days following 5 days of ceftriaxone or saline pretreatment. On the days of testing, animals were lightly restrained in thin cotton towels secured with rubber bands with their tails exposed. A Life Science Instruments, Model 33 Tail-Flick Analgesia Meter (Woodland Hills, California, USA) was used to measure tail-flick latency in response to a radiant heat source focused on approximately 25-mm 2 area of the distal tail. Maximum tail-flick latency was set to 10 s. Before nicotine administration, baseline latencies for each animal were calculated from three tail-flick measurements spaced 5-7 min apart. After nicotine or saline administration, five tailflick latencies were measured at 2, 4, 6, 8, and 10 min post injection. To prevent tissue damage and inaccurate tail-flick latencies, a slightly more proximal (approximately 0.5 cm) section of each animal's tail was used to record latencies on consecutive days.
Data analysis
Response-latency values were expressed as a percentage of maximum possible effect (%MPE): %MPE = (drug response latency-baseline response latency)/(10s -baseline response latency) Â 100%. Two-way repeated-measures analyses of variance followed by Bonferroni's post-hoc comparisons identified differences between individual treatment groups. Values of P less than 0.05 were considered significant.
Results
The maximum analgesic effect of nicotine occurred at 2 min post injection. The present data are consistent with previous nicotine tail-flick experiments demonstrating similar dose and time course effects [15] . Figure 1 displays the time course of the analgesic effect of nicotine or nicotine and ceftriaxone as a function of %MPE. Figure 2 displays the average ± SD of the 2 min %MPE on days 1, 4, and 7. A two-way analyses of variance conducted on the 2-min %MPE on days 1, 4, and 7 revealed significant group [F(4,105) = 217.0; P < 0.0001] and day [F(2,105) = 7.580; P < 0.001] effects as well as a significant interaction [F(8,105) = 6.982; P < 0.0001]. Post-hoc comparisons revealed that acute (day 1) nicotine analgesia was enhanced by ceftriaxone at a dose of 2.5 mg/kg, (P < 0.01 compared with saline/nicotine, 2.5 mg/kg) but not 1.0 mg/kg (P > 0.05 compared with saline/nicotine, 1.0 mg/kg). On days 4 and 7, ceftriaxone dose dependently enhanced nicotine analgesia compared with saline-matched controls. By day 7, nicotine (2.5 mg/ kg) alone still exerted an analgesic effect (P < 0.01 compared with saline/saline, not indicated on Fig. 2) ; however, this effect was drastically reduced compared with the %MPE on day 1 (21.2% on day 7 vs. 60.7% on day 1). In contrast, the %MPE exhibited by ceftriaxone/ nicotine (2.5 mg/kg) animals was unchanged from day 1 to day 7 (78.6% on day 1 vs. 87.5% on day 7) suggesting that ceftriaxone prevented tolerance to nicotine (2.5 mg/kg) analgesia. Nicotine (1.0 mg/kg) alone no longer exerted analgesia by day 4 (P > 0.05 compared with saline/saline). However, ceftriaxone/nicotine (1.0 mg/kg)-treated animals exhibited analgesia on days 1, 4, and 7 (P < 0.001 vs. saline/saline on each day), indicating that ceftriaxone prevented nicotine (1.0 mg/kg) analgesic tolerance. In a separate preliminary study, no analgesia was observed following ceftriaxone (200 mg/kg), pretreatment for 5 days compared with saline-matched controls (data not shown).
Discussion
Ceftriaxone activates GLT-1 [9] and enhances clearance of extracellular glutamate [10] . Rats pretreated for five consecutive days with ceftriaxone displayed an enhancement of acute nicotine antinociception. In addition, ceftriaxone coadministered with nicotine over the course of 1 week prevented antinociceptive tolerance. These results suggest that extracellular glutamate plays a key role in nicotine analgesia.
Nicotine dependence studies have suggested that chronic nicotine administration is accompanied by enhanced glutamatergic transmission and that N-methyl-D-aspartate and mGlu (5) antagonists may be effective for treating nicotine dependence (reviewed by [16] ). Comparatively little is known about the role of the glutamate system in nicotine analgesia. Iwamoto [17] demonstrated that nicotine antinociception is mediated by the tegmental pedunculopontine and dorsal raphe nuclei. These two areas have been shown to receive dense glutamatergic projections and express glutamate receptors [18] [19] [20] . Although it is unclear from the results of the present study precisely how glutamate is involved in the development of nicotine antinociceptive tolerance, it can be postulated that repeated nicotine administration results in a gradual enhancement of glutamatergic transmission in brain areas responsible for pain processing. Ceftriaxone's activation of GLT-1 enhances cellular uptake of glutamate preventing extracellular glutamate levels from rising during repeated nicotine administration and preserving nicotine's analgesic efficacy.
Pretreatment with ceftriaxone dose dependently reduces morphine analgesic tolerance using the hot-plate assay [12] . In that study, the effects of ceftriaxone were prevented by pharmacologic blockade of GLT-1. These findings, taken together with the results of the current study, suggest that increased extracellular glutamate is a common factor in the development of analgesic tolerance exhibited by drugs with different mechanisms of action. Although the effects of an acute injection of ceftriaxone on nicotine antinociception were not investigated in this study, behavioral, cellular, and neurochemical data from a number of laboratories indicate that repeated administration of ceftriaxone is required for the expres-sion of antiglutamate effects [9, 21, 22] . Moreover, it has been demonstrated that a single injection of ceftriaxone does not alter behavioral responses to morphine or amphetamine [23, 24] . This suggests that instead of exerting an acute effect, repeated ceftriaxone administration causes an upregulation in GLT-1 activity and expression [9] that increases the efficiency of glutamate uptake that may be necessary for the prevention of analgesic tolerance.
The dose of ceftriaxone used in this study (200 mg/kg) produces a significant and sustained reduction in extracellular glutamate [10] ; however, this dose is equivalent to a clinical dose of 13 mg/day, significantly greater than the typical dose of 2 mg/day administered to patients as an antibiotic [9] . Multiple doses of ceftriaxone were not evaluated in the current study; however, lower doses of ceftriaxone have been shown to be effective in enhancing morphine analgesia [12] . These studies may have important clinical implications for the management of chronic pain. Clavulanic acid is a b-lactamase inhibitor that is structurally similar to ceftriaxone but lacks antibacterial efficacy. Future studies will evaluate the pharmacovigilance and effectiveness of this and other drugs as GLT-1 activators. Chronic pain sufferers often experience tolerance to pain medication while also being exposed to dangerously addictive drugs. Research highlighting the mechanisms of analgesic tolerance may promote the development of adjuvant therapies for the treatment of pain.
Conclusion
Pretreatment with the b-lactam antibiotic and glutamate transporter activator ceftriaxone dose dependently potentiates nicotine antinociception. Continued enhancement of extracellular glutamate clearance prevents nicotine analgesic tolerance.
